Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise independent medical judgment in the context of individual patient care, taking into account the patient's specific condition, comorbidities, and current clinical guidelines. Always consult official drug prescribing information and current clinical practice guidelines. This resource is not a substitute for direct patient care, consultation with specialists, or current literature review.

Systemic Onset Juvenile Idiopathic Arthritis (SoJIA)

Overview

• Definition: Systemic onset juvenile idiopathic arthritis (SoJIA), also known as Still's disease in adults, is a distinct subtype of juvenile idiopathic arthritis characterized by prominent systemic inflammatory features (e.g., daily fevers, rash, serositis, lymphadenopathy, hepatosplenomegaly) occurring concurrently with or preceding the onset of arthritis. It is classified as an autoinflammatory disease due to dysregulation of innate immunity.
• Epidemiology: SoJIA accounts for approximately 10-20% of all JIA cases. Its incidence varies globally, estimated between 0.5 to 1.5 per 100,000 children per year. It affects males and females equally, unlike other JIA subtypes. Onset can occur at any age during childhood, with peaks typically in early childhood (1-5 years) and adolescence.
• Classification: SoJIA is one of the seven categories of JIA as defined by the International League of Associations for Rheumatology (ILAR) classification criteria. These criteria require arthritis in one or more joints, lasting at least 6 weeks, and are accompanied or preceded by at least 2 weeks of daily fever (quotidian pattern) plus one or more of the following: evanescent erythematous rash, generalized lymph node enlargement, hepatomegaly and/or splenomegaly, or serositis.

Pathophysiology

• Mechanism: SoJIA is considered an autoinflammatory disease, characterized by dysregulation of the innate immune system. The pathogenesis involves an overproduction of pro-inflammatory cytokines, particularly Interleukin-1 (IL-1) and Interleukin-6 (IL-6), which drive the systemic inflammation.
  • IL-1 and IL-6 Pathways: IL-1β and IL-6 are key mediators. IL-1β drives fever, leukocytosis, and acute phase reactants, while IL-6 contributes to fever, CRP elevation, thrombocytosis, and hyperferritinemia. These cytokines promote inflammation without the clear autoantigen-driven mechanism seen in autoimmune diseases.
  • Neutrophil Activation: Neutrophils play a central role, contributing to inflammation and potentially to macrophage activation syndrome (MAS).
  • Macrophage Activation: Macrophages are also activated, contributing to cytokine storm, especially in MAS.
  • Genetic Predisposition: No single gene is strongly associated, but multiple susceptibility loci have been identified (e.g., variants in PTPN22, IL-10, IL-6, NLRP3), suggesting polygenic inheritance.
• Risk Factors:
  • Genetic Predisposition: Certain HLA alleles (e.g., HLA-DR4, HLA-DRB111, HLA-DRB115) and non-HLA genes are associated, but no strong single gene link.
  • Environmental Triggers: Infections (viral, bacterial) are often implicated as triggers in genetically predisposed individuals, initiating the inflammatory cascade.
• Protective Factors: No specific protective factors are well-established for preventing the onset of SoJIA. Early diagnosis and appropriate treatment may prevent long-term complications.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Fever: High-spiking, quotidian (daily) fever, typically reaching ≥39°C (102.2°F) once or twice a day, usually in the late afternoon or evening, returning to baseline or subnormal levels between spikes. Often persists for weeks to months.
  • Rash: Evanescent, salmon-pink, macular or maculopapular rash, often appearing with fever spikes and fading as the fever subsides. Commonly seen on the trunk and proximal extremities, sometimes with Koebner phenomenon (linear rash from scratching).
  • Arthritis: Oligoarticular or polyarticular arthritis, developing concurrently with or often after the systemic features. Any joint can be affected, but knees, wrists, ankles, and cervical spine are common. Can be severe and destructive.
• Early Signs:
  • Persistent quotidian fevers.
  • Evanescent rash.
  • Myalgia, malaise, irritability.
  • Sore throat (non-exudative).
  • Lymphadenopathy (generalized).
  • Hepatosplenomegaly.
• Advanced Signs:
  • Progressive polyarthritis with joint contractures and erosions.
  • Growth failure.
  • Osteoporosis.
  • Cardiac involvement (pericarditis, myocarditis).
  • Pulmonary involvement (pleuritis, interstitial lung disease, pulmonary hypertension, alveolar proteinosis).
  • Macrophage Activation Syndrome (MAS): a life-threatening complication.
• Atypical Presentations:
  • Arthritis preceding systemic features (less common).
  • Dominant cardiac or pulmonary involvement at presentation.
  • Prolonged fever without clear rash or arthritis initially.
  • Presentation mimicking sepsis or malignancy.

Physical Examination

• Inspection:
  • Rash: Examine skin for evanescent salmon-pink macules, especially during fever spikes.
  • Joints: Look for swelling, erythema, warmth, limited range of motion, deformities (especially wrists, knees, ankles, small joints).
  • General: Assess for pallor, signs of distress, growth parameters.
  • Lymph nodes: Palpate for generalized lymphadenopathy (cervical, axillary, inguinal).
• Palpation:
  • Joints: Palpate for warmth, tenderness, effusion, synovial hypertrophy.
  • Abdomen: Palpate for hepatomegaly (liver span >2 cm below costal margin) and splenomegaly.
• Special Tests:
  • Joint Range of Motion: Actively and passively assess all major joints to identify limitations and pain.
  • Cardiac Auscultation: Listen for pericardial friction rub (pericarditis) or new murmurs (myocarditis).
  • Pulmonary Auscultation: Listen for diminished breath sounds or rubs (pleuritis).

Diagnostic Approach

History Taking

• Key Questions:
  • Fever characteristics: Pattern (daily spike, returning to baseline), height, duration.
  • Rash characteristics: Timing relative to fever, appearance, duration, location.
  • Joint symptoms: Number of affected joints, stiffness (especially morning), pain, swelling, limitation of movement, symmetry.
  • Systemic symptoms: Myalgia, fatigue, sore throat, weight loss, abdominal pain, chest pain, shortness of breath.
  • Past medical history: Recent infections, travel, medications, family history of autoimmune/autoinflammatory diseases.
  • Developmental history: Growth parameters.
• Red Flags:
  • Sudden worsening of systemic symptoms: Rapid decline in level of consciousness, unexplained severe abdominal pain, new bleeding, significant pallor, jaundice.
  • Persistent high fever despite treatment.
  • New onset significant lymphadenopathy, hepatosplenomegaly, or serositis.
  • Unexplained severe laboratory abnormalities: Rapidly declining cell counts (pancytopenia), dramatically rising ferritin (often >10,000 ng/mL), rising liver enzymes, coagulopathy (elevated PT/PTT, low fibrinogen). These are highly suggestive of Macrophage Activation Syndrome (MAS), a medical emergency.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with differential: Typically shows leukocytosis (often >15,000/µL) with neutrophilia, thrombocytosis (platelets often >500,000/µL), and anemia (normocytic, normochromic, consistent with chronic inflammation).
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Markedly elevated during active disease (ESR >50 mm/hr, CRP >30 mg/L or higher).
  • Ferritin: Often significantly elevated (>1000 ng/mL), can be extremely high (>10,000 ng/mL) in MAS. It is an acute phase reactant but also a marker of macrophage activation.
  • Liver Function Tests (LFTs): May show elevated AST/ALT due to liver involvement or MAS.
  • Coagulation Profile (PT, PTT, Fibrinogen): Typically normal in active SoJIA, but critical for MAS evaluation (prolonged PT/PTT, decreased fibrinogen in MAS).
  • Creatinine Kinase (CK): May be elevated if significant myositis.
  • Urinalysis: To rule out renal involvement or other causes of fever.
• Confirmatory:
  • There are no "confirmatory" lab tests unique to SoJIA; diagnosis relies on clinical criteria supported by laboratory findings that indicate systemic inflammation.
  • Autoantibodies: Antinuclear Antibody (ANA), Rheumatoid Factor (RF), and anti-cyclic citrullinated peptide (anti-CCP) antibodies are typically negative in SoJIA (<10% positive for ANA, <5% for RF). Their positivity suggests other JIA subtypes.
  • Exclusion of other conditions: Blood cultures, viral serologies (EBV, CMV, parvovirus B19), tuberculosis testing, tumor markers (e.g., LDH) to rule out infections, malignancies, or other rheumatic diseases.
  • Serum Amyloid A (SAA): Very high during active disease, another useful marker of inflammation.
• Monitoring:
  • CBC, ESR, CRP, Ferritin, LFTs: Regularly monitored to assess disease activity, response to treatment, and for early detection of MAS.
  • Growth velocity: To monitor for impact on growth.
  • Bone mineral density: To monitor for osteoporosis due to chronic inflammation and steroid use.

Imaging

• Recommended:
  • Plain Radiographs (X-rays):
    • Affected joints: To assess for effusions, soft tissue swelling, periarticular osteopenia, and later, joint space narrowing, erosions, and epiphyseal overgrowth/fusion.
    • Cervical spine: To assess for C1-C2 fusion, especially in children with neck pain and stiffness.
  • Echocardiogram: Recommended at diagnosis and periodically to screen for cardiac involvement (pericardial effusion, myocarditis, pulmonary hypertension).
• Advanced:
  • Magnetic Resonance Imaging (MRI):
    • Joints: More sensitive than X-rays for detecting early synovitis, cartilage damage, bone marrow edema, and erosions. Useful when X-rays are normal but clinical suspicion is high.
    • Serositis: Can detect pericardial or pleural effusions.
  • Ultrasound (US):
    • Joints: Useful for detecting effusions, synovitis, and tenosynovitis, and for guiding aspirations or injections.
    • Abdomen: To assess for hepatosplenomegaly.
  • CT scan: Not routinely used for diagnosis but may be considered for severe pulmonary involvement or to rule out malignancy.
  • PET-CT: Can sometimes be used in complex cases to rule out malignancy or localize inflammatory activity, but not standard.

Management

Acute Management

• Immediate (Stabilization for Severe Systemic Illness/MAS Suspicion):
  • Hospitalization: For patients with severe systemic features, suspected MAS, or diagnostic uncertainty.
  • Close Monitoring: Vital signs, fluid balance, mental status, cardiac function.
  • Corticosteroids (IV): For severe systemic inflammation or suspected MAS.
    • Methylprednisolone pulse therapy: 30 mg/kg/dose (max 1000 mg) IV daily for 1-3 days for severe systemic features or initial MAS management.
• Stabilization:
  • High-dose Oral Corticosteroids: Following IV pulses, transition to oral prednisone (1-2 mg/kg/day, max 60 mg/day) for 2-4 weeks, then slowly taper.
  • Empiric Antibiotics: Consider if infection cannot be immediately ruled out.
  • Fluid and Electrolyte Management: Address dehydration or third spacing.
  • Pain Control: Analgesics as needed.
• Emergency (Macrophage Activation Syndrome - MAS):
  • Diagnosis: Suspect MAS if sudden worsening of systemic symptoms, cytopenias (anemia, leukopenia, thrombocytopenia), coagulopathy (prolonged PT/PTT, low fibrinogen), elevated liver enzymes, very high ferritin (>10,000 ng/mL often), and CNS symptoms. Diagnosis often guided by the 2016 Classification Criteria for MAS in JIA (which include specific laboratory and clinical parameters).
  • Aggressive Immunosuppression:
    • High-dose IV Corticosteroids: Methylprednisolone 30 mg/kg/dose (max 1000 mg) IV daily for 3 days, followed by tapering.
    • Cyclosporine A (CsA): Often added if no rapid response to corticosteroids (start 2-5 mg/kg/day divided twice daily, titrate to levels).
    • Anakinra: An IL-1 receptor antagonist, often used as first-line for MAS, especially if high ferritin and CNS involvement. Doses up to 10 mg/kg/day (or higher for severe MAS) subcutaneously, divided BID.
    • Etoposide: For refractory MAS, given by hematologist/oncologist, due to significant side effects.

Chronic Management

• Pharmacological:
  • First-Line for Systemic Features:
    • Glucocorticoids: Prednisone (0.5-2 mg/kg/day, typically tapered rapidly once systemic features are controlled) are effective for systemic features but associated with significant side effects with prolonged use.
    • Non-steroidal Anti-inflammatory Drugs (NSAIDs): Can be used for mild arthritis or in conjunction with other agents. Naproxen (10-20 mg/kg/day divided BID), Ibuprofen (30-40 mg/kg/day divided TID/QID). Less effective for systemic features.
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs):
    • Conventional Synthetic DMARDs (csDMARDs): Methotrexate (10-15 mg/m2/week orally or subcutaneously) is often used for persistent arthritis but has limited efficacy for systemic features of SoJIA.
    • Biologic DMARDs (bDMARDs): The mainstay of treatment for SoJIA, especially those with persistent systemic features or steroid-dependence.
      • Interleukin-1 (IL-1) Inhibitors: Highly effective for systemic features.
        • Anakinra: (IL-1R antagonist) 1-2 mg/kg/day subcutaneously (max 100 mg/day), can be escalated to 4-8 mg/kg/day for severe disease or MAS prevention. Rapid onset of action.
        • Canakinumab: (Anti-IL-1β monoclonal antibody) 4 mg/kg subcutaneously every 4 weeks. Longer half-life, suitable for long-term treatment.
        • Rilonacept: (IL-1 Trap) 4.4 mg/kg loading dose, then 2.2 mg/kg weekly subcutaneously.
      • Interleukin-6 (IL-6) Inhibitors: Highly effective for systemic features and arthritis.
        • Tocilizumab: (Anti-IL-6R monoclonal antibody) IV: 8 mg/kg every 4 weeks for patients ≥30 kg; 12 mg/kg every 4 weeks for patients <30 kg. SC: 162 mg every 2 weeks for patients ≥30 kg; 162 mg every 3 weeks for patients 10 to <30 kg.
      • JAK Inhibitors: Emerging class, approved for adult Still's disease, under investigation for pediatric SoJIA.
        • Tofacitinib: (JAK1/3 inhibitor) Oral, dosages vary by age/weight.
  • Intravenous Immunoglobulin (IVIG): Rarely used for refractory cases or as adjunctive therapy in MAS, but not standard.
• Non-pharmacological:
  • Physical Therapy (PT) and Occupational Therapy (OT): Essential to maintain joint range of motion, muscle strength, prevent contractures, and improve functional abilities.
  • Nutritional Support: Address growth failure and osteoporosis; ensure adequate calcium and vitamin D intake.
  • Psychological Support: For the child and family, addressing chronic illness burden.
  • Vaccinations: Ensure up-to-date immunizations, but avoid live attenuated vaccines while on immunosuppressants (unless low-dose steroids).
• Monitoring:
  • Clinical Monitoring: Regular assessment of disease activity (fever, rash, arthritis, systemic symptoms), growth, development, and steroid side effects.
  • Laboratory Monitoring: ESR, CRP, CBC, LFTs every 4-8 weeks, or more frequently during active disease/treatment changes. Screening for infections (e.g., TB screening before biologics).
  • Ophthalmologic Screening: Annually, although uveitis is rare in SoJIA.
  • Bone Density Screening: Consider DEXA scans for prolonged steroid use.

Treatment Algorithms

• First-Line:
  • Initial Presentation (Mild systemic, moderate arthritis): NSAIDs ± low-dose glucocorticoids for symptomatic relief. If systemic features prominent or persistent, proceed quickly to biologic therapy.
  • Prominent Systemic Features (High fever, serositis, organomegaly, high inflammatory markers): Initiate systemic glucocorticoids (prednisone 1-2 mg/kg/day or IV methylprednisolone pulses) and simultaneously start an IL-1 inhibitor (Anakinra or Canakinumab) or an IL-6 inhibitor (Tocilizumab). Taper steroids quickly once systemic symptoms are controlled.
• Second-Line:
  • Inadequate response to initial biologic: Switch to a different class of biologic (e.g., if on IL-1 inhibitor, switch to IL-6 inhibitor, or vice versa).
  • Persistent arthritis without systemic features: Consider adding Methotrexate or using a biologic with strong arthritis efficacy (e.g., Tocilizumab, or TNF inhibitors if specific indications arise, although less effective for systemic SoJIA).
• Refractory Cases:
  • Persistent active disease despite multiple biologics:
    • Consider combination therapy (e.g., a biologic with methotrexate, though data is limited).
    • Explore alternative mechanisms (e.g., JAK inhibitors if available/approved).
    • Re-evaluate diagnosis, consider genetic autoinflammatory conditions, or malignancy mimics.
    • Consult with a specialized pediatric rheumatology center.
  • Recurrent MAS: May require chronic IL-1 blockade or continuous immunosuppression.

Complications

• Common:
  • Anemia of chronic disease: Due to ongoing inflammation.
  • Growth retardation: Due to chronic inflammation, corticosteroid use, and nutritional deficiencies.
  • Osteoporosis: Due to chronic inflammation, inactivity, and long-term corticosteroid use.
  • Joint damage: Progressive, erosive arthritis leading to pain, stiffness, and deformities, especially if disease is uncontrolled.
• Serious:
  • Macrophage Activation Syndrome (MAS): A life-threatening hyperinflammatory state characterized by uncontrolled activation and proliferation of T lymphocytes and macrophages, leading to widespread hemophagocytosis. Manifests with high fever, hepatosplenomegaly, lymphadenopathy, CNS dysfunction, bleeding diathesis, cytopenias, coagulopathy, and extreme hyperferritinemia.
  • Cardiac complications: Pericarditis (most common), myocarditis, valvulitis, coronary artery involvement (rare but serious).
  • Pulmonary complications: Pleuritis, interstitial lung disease (ILD), alveolar proteinosis, pulmonary hypertension (can be life-threatening).
  • Amyloidosis (AA amyloidosis): A rare but severe long-term complication of chronic inflammation, leading to kidney failure and other organ damage.
• Long-term:
  • Chronic arthritis and functional disability: Up to 50% of patients may have chronic active arthritis leading to joint damage and reduced function.
  • Steroid-related complications: Cushingoid features, cataracts, glaucoma, hypertension, diabetes, increased infection risk, bone fragility.
  • Increased risk of infections: Due to immunosuppression.
  • Psychosocial impact: Chronic illness can affect education, social development, and mental health.

Prognosis

• Factors:
  • Severity of systemic features at onset: More severe systemic features may predict a relapsing course.
  • Response to initial therapy: Early and sustained response to IL-1 or IL-6 inhibitors is associated with better outcomes.
  • Presence of MAS: MAS episodes increase morbidity and mortality.
  • Type of disease course:
    • Monocyclic (30-50%): Single episode, complete remission.
    • Polycyclic (20-30%): Recurrent episodes with periods of remission.
    • Chronic articular (20-40%): Persistent arthritis often with less prominent systemic features, leading to significant joint damage.
  • Age of onset: Younger age at onset may be associated with more severe disease.
• Survival: Overall prognosis has significantly improved with the advent of biologic therapies. Mortality rates, once 2-4%, have decreased substantially due to effective control of MAS and chronic inflammation.
• Quality of Life: Significantly impacted by chronic pain, fatigue, joint damage, growth delay, and treatment side effects. Early and aggressive treatment aims to improve functional outcomes and quality of life, allowing normal schooling and social integration. Many patients achieve remission or low disease activity, but a significant proportion experience chronic arthritis.

Prevention

• Primary: Currently, there are no known primary prevention strategies for SoJIA as its exact triggers are not fully understood.
• Secondary:
  • Early Diagnosis: Prompt recognition of signs and symptoms of SoJIA is critical to initiate treatment early and prevent disease progression and complications.
  • Aggressive initial treatment: Using IL-1 or IL-6 inhibitors early in the disease course to suppress inflammation and potentially induce remission, aiming to prevent chronic disease and MAS.
• Tertiary:
  • Prevention of Complications:
    • MAS prevention: Close monitoring for MAS, especially during flares or infections; prompt treatment if suspected.
    • Joint damage prevention: Aggressive control of arthritis with DMARDs and biologics, combined with physical therapy.
    • Osteoporosis prevention: Adequate calcium and vitamin D intake, bisphosphonates if needed, and judicious use of corticosteroids.
    • Growth failure prevention: Early disease control, growth hormone therapy in selected cases.
  • Regular monitoring: Routine clinical and laboratory assessments to detect flares or complications early.

Special Populations

• Pediatric: SoJIA is primarily a pediatric disease. All management considerations are primarily tailored to children and adolescents, considering growth and development.
  • Growth: Chronic inflammation and high-dose steroids can significantly impair growth. Close monitoring of growth charts is essential.
  • Bone Health: High risk of osteoporosis. Vitamin D and calcium supplementation, and bisphosphonates if severe.
  • Vaccinations: Live vaccines should generally be avoided while on significant immunosuppression.
• Geriatric: SoJIA does not occur in geriatric populations. However, its adult counterpart, Adult-Onset Still's Disease (AOSD), shares the same clinical features and treatment principles. Geriatric patients with AOSD may have more comorbidities and altered drug metabolism, requiring careful medication dosing and monitoring for side effects (e.g., cardiotoxicity, infection risk).
• Pregnancy:
  • For female SoJIA patients reaching childbearing age: Pregnancy in patients with SoJIA (or AOSD) requires careful planning and multidisciplinary management.
  • Disease activity: Ideally, conception should occur during periods of disease remission or low activity.
  • Medication management:
    • NSAIDs: Generally avoided in the third trimester due to risk of premature ductal closure.
    • Corticosteroids: Low-dose prednisone is generally considered safe.
    • Methotrexate: Contraindicated due to teratogenicity.
    • Biologics:
      • Tocilizumab, Canakinumab: Limited data, but often continued if disease activity is high, with some guidelines recommending discontinuation in late third trimester. IgG antibodies generally cross the placenta, so there is potential for neonatal immunosuppression.
      • Anakinra: Shorter half-life, considered by some as safer than other biologics due to minimal placental transfer and rapid clearance.
  • Monitoring: Close monitoring of disease activity, fetal growth, and potential complications.
• Comorbidities:
  • Infections: Patients on immunosuppression are at increased risk. Prompt evaluation and aggressive management of suspected infections.
  • Cardiovascular disease: Long-term inflammation may increase cardiovascular risk.
  • Chronic kidney disease: Rare, usually due to MAS or amyloidosis.
  • Psychological distress: Anxiety, depression. Provide mental health support.

Clinical Pearls

• Diagnostic:
  • "Pink and perfuse": A child with high fever but appearing relatively well between fever spikes, often points towards SoJIA rather than bacterial sepsis.
  • Extreme hyperferritinemia: While not specific, a ferritin level >1000 ng/mL, especially >10,000 ng/mL, should strongly raise suspicion for SoJIA or MAS.
  • Negative autoantibodies: ANA, RF, anti-CCP are typically negative; positive results warrant re-evaluation for other JIA subtypes or systemic lupus erythematosus.
  • Rule out mimics: Always consider infections (viral, bacterial, fungal), malignancies (leukemia, lymphoma, neuroblastoma), and other autoinflammatory syndromes.
• Treatment:
  • Early and aggressive use of biologics: For systemic features, early introduction of IL-1 or IL-6 inhibitors can prevent steroid dependence, chronic arthritis, and MAS.
  • Steroid-sparing strategy: Aim to rapidly taper and discontinue corticosteroids once biologics take effect to minimize long-term side effects.
  • MAS readiness: Always have a high index of suspicion for MAS; educate families on warning signs. Prompt treatment is life-saving.
• Pitfalls:
  • Misdiagnosing as infection or malignancy: Delaying diagnosis and appropriate treatment due to focus on ruling out infectious or oncologic causes.
  • Over-reliance on NSAIDs or Methotrexate: These are often insufficient for controlling systemic SoJIA and can delay effective biologic therapy.
  • Under-treatment of MAS: Failure to recognize or aggressively treat MAS can lead to fatal outcomes.
  • Not tapering steroids quickly enough: Leading to unnecessary long-term steroid side effects.
  • Missing cardiac or pulmonary complications: Regular screening (e.g., echocardiogram) is crucial.

Recent Updates

• Guidelines: The American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) have updated recommendations emphasizing early use of biologics (IL-1 or IL-6 inhibitors) for SoJIA with prominent systemic features, moving away from initial reliance on csDMARDs alone.
• Evidence:
  • Strong evidence supports the superior efficacy of IL-1 and IL-6 inhibitors over conventional DMARDs for controlling systemic features and improving long-term outcomes in SoJIA.
  • Increasing recognition of the spectrum of pulmonary complications in SoJIA, including alveolar proteinosis and interstitial lung disease, requiring specialized management.
  • Emerging role of JAK inhibitors (e.g., Tofacitinib, Baricitinib) for adult-onset Still's disease, with ongoing trials for pediatric SoJIA.
• Controversies:
  • Optimal timing and sequencing of biologics: While consensus supports early biologics, the exact choice between IL-1 and IL-6 inhibitors at diagnosis, and the optimal duration of therapy, are still debated and often individualized.
  • Prevention of MAS: While IL-1 inhibitors are used for MAS treatment, their role in primary prevention of MAS in all SoJIA patients is still being elucidated.
  • Phenotype-driven treatment: Ongoing research aims to identify biomarkers that predict disease course (systemic vs. articular dominant) and response to specific therapies, to further personalize treatment.

Key References

• Guidelines:
  • Ringold, S., et al. (2018). "2018 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Systemic Juvenile Idiopathic Arthritis." Arthritis Care & Research, 70(5), 643-659.
  • Haddad, E., et al. (2020). "EULAR recommendations for the management of adult-onset Still's disease." Annals of the Rheumatic Diseases, 79(1), 1-13. (Relevant for AOSD, shares many principles with SoJIA).
  • Prakken, B., et al. (2011). "Juvenile idiopathic arthritis. Nat Rev Dis Primers". (Comprehensive review of JIA).
• Studies:
  • De Benedetti, F., et al. (2012). "Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis and Glucocorticoid-Resistant Disease." New England Journal of Medicine, 367(24), 2287-2296. (Landmark trial for Canakinumab).
  • Ruperto, N., et al. (2012). "A randomized, double-blind, placebo-controlled trial of tocilizumab in systemic juvenile idiopathic arthritis." Arthritis & Rheumatism, 64(7), 2419-2428. (Landmark trial for Tocilizumab).
  • Schulert, G. S., & Cron, R. Q. (2019). "Macrophage Activation Syndrome and Cytokine Storm Syndromes." Pediatric Clinics of North America, 66(1), 263-279.
  • Shimizu, M., et al. (2018). "Development of the 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis." Annals of the Rheumatic Diseases, 75(6), 1017-1025.
• Reviews:
  • Mellins, E. D., & Macaubas, C. (2018). "Systemic Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment." Current Opinion in Rheumatology, 30(2), 173-181.
  • Vojinovic, J., & Stojanovic, R. (2018). "Systemic onset juvenile idiopathic arthritis: Treatment landscape and future directions." Pediatric Rheumatology, 16(1), 1-10.